. 2023 Mar 23;26(2):227–236. doi: 10.1007/s11102-023-01310-x

Table 1.

Baseline characteristics

Sex	Female 42% (n = 61) Male 58% (n = 83)
Age	61 years (IQR: 50–70) • Females 61 (IQR 47–70) • Males 61 (IQR 52–70)
Tumour volume (mm ³ )	6224 (IQR: 3876–9646)
Invasive (Knosp ≥ 3) Non-invasive (Knosp ≤ 2)	30.6% (n = 44) 69.4% (n = 100)
Indication for surgery • Visual disturbances • Tumour growth • Headache • Apoplexy	87.5% (n = 126) 10.3% (n = 15) 0.7% (n = 1) 1.4% (n = 2)
PitNET subtype • Gonadotroph • Corticotroph • Plurihormonal Pit-1 tumours • Somato-lactotroph • Plurihormonal (SF-1 and Pit-1) • Double PitNET • Hormone and transcription factor negative	80.6% (n = 116) 13.2% (n = 19) 1.4% (n = 2) 1.4% (n = 2) 0.7% (n = 1) 0.7% (n = 1) 2.0% (n = 3)

Sex

Female 42% (n = 61)
Male 58% (n = 83)

Age

61 years (IQR: 50–70)

• Females 61 (IQR 47–70)

• Males 61 (IQR 52–70)

Tumour volume (mm ³ )

6224 (IQR: 3876–9646)

Invasive (Knosp ≥ 3)

Non-invasive (Knosp ≤ 2)

30.6% (n = 44)

69.4% (n = 100)

Indication for surgery

• Visual disturbances

• Tumour growth

• Headache

• Apoplexy

87.5% (n = 126)

10.3% (n = 15)

0.7% (n = 1)

1.4% (n = 2)

PitNET subtype

• Gonadotroph

• Corticotroph

• Plurihormonal Pit-1 tumours

• Somato-lactotroph

• Plurihormonal (SF-1 and Pit-1)

• Double PitNET

• Hormone and transcription factor negative

80.6% (n = 116)

13.2% (n = 19)

1.4% (n = 2)

0.7% (n = 1)

2.0% (n = 3)

Numbers are given as percentages or median with interquartile range (IQR).